Literature DB >> 12213408

PCR-generated linear DNA fragments utilized as a hantavirus DNA vaccine.

P Johansson1, T Lindgren, M Lundström, A Holmström, F Elgh, G Bucht.   

Abstract

The field of DNA vaccines has grown rapidly, and since most such vaccines involve the inoculation of large circular DNA molecules previously propagated in bacteria, several inconveniences (e.g. the presence of antibiotic resistance genes, impurities from bacterial cultures or inefficient uptake of the large and bulky plasmid DNA molecules to the nucleus) are debated. In this study, we have explored the possibility of using smaller and more flexible PCR-generated linear DNA fragments instead. Phosphorothioate (PTO)-modified primers were used successfully to protect the PCR-generated DNA fragments from exonuclease degradation, and by using a nuclear localization signal-peptide to target the linear DNA to the nucleus the immune response against the encoded antigen was further improved. This approach was tested in cell culture using a sensitive reporter system and in vivo with DNA encoding the amino-terminus of the Puumala hantavirus nucleocapsid protein. Our results indicate that linear DNA fragments have a great potential as a genetic vaccine and phosphorothioate modification in combination with a nuclear localization signal peptide increase the stability and targets the linear DNA molecules to the nucleus resulting in an improved biological response examined both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213408     DOI: 10.1016/s0264-410x(02)00265-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  The nuclear pore complex: the gateway to successful nonviral gene delivery.

Authors:  Marieke A E M van der Aa; Enrico Mastrobattista; Ronald S Oosting; Wim E Hennink; Gerben A Koning; Daan J A Crommelin
Journal:  Pharm Res       Date:  2006-03-15       Impact factor: 4.200

2.  Exogenous DNA Loading into Extracellular Vesicles via Electroporation is Size-Dependent and Enables Limited Gene Delivery.

Authors:  Tek N Lamichhane; Rahul S Raiker; Steven M Jay
Journal:  Mol Pharm       Date:  2015-09-23       Impact factor: 4.939

Review 3.  A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium.

Authors:  Adarsha Koirala; Shannon M Conley; Muna I Naash
Journal:  Biomaterials       Date:  2013-06-22       Impact factor: 12.479

Review 4.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

Review 5.  New ecological aspects of hantavirus infection: a change of a paradigm and a challenge of prevention--a review.

Authors:  Martin Zeier; Michaela Handermann; Udo Bahr; Baldur Rensch; Sandra Müller; Roland Kehm; Walter Muranyi; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

6.  Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.

Authors:  Marc S Weinberg; Patrick Arbuthnot
Journal:  Genome Med       Date:  2010-04-28       Impact factor: 11.117

7.  A novel micro-linear vector for in vitro and in vivo gene delivery and its application for EBV positive tumors.

Authors:  Hong-Sheng Wang; Zhuo-Jia Chen; Ge Zhang; Xue-Ling Ou; Xiang-Ling Yang; Chris K C Wong; John P Giesy; Jun Du; Shou-Yi Chen
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

8.  Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.

Authors:  Nina Lagerqvist; Jonas Näslund; Ake Lundkvist; Michèle Bouloy; Clas Ahlm; Göran Bucht
Journal:  Virol J       Date:  2009-01-17       Impact factor: 4.099

Review 9.  Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses.

Authors:  Joseph W Golden; Christopher D Hammerbeck; Eric M Mucker; Rebecca L Brocato
Journal:  Biomed Res Int       Date:  2015-07-21       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.